We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+10.28%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.07B
AUM Growth
-$11.6M
Cap. Flow
-$144M
Cap. Flow %
-2.83%
Top 10 Hldgs %
24.83%
Holding
159
New
22
Increased
53
Reduced
27
Closed
17

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$48.3M
2
FLYW icon
Flywire
FLYW
+$47.9M
3
DLO icon
dLocal
DLO
+$36.1M
4
DV icon
DoubleVerify
DV
+$35.7M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$31.3M

Top Sells

Rank Stock Value
1
CTAS icon
Cintas
CTAS
+$108M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$106M
3
BHVN icon
Biohaven
BHVN
+$74.9M
4
KNBE
KnowBe4, Inc. Class A Common Stock
KNBE
+$68M
5
MDB icon
MongoDB
MDB
+$57.4M

Sector Composition

Rank Sector Weight
1 Healthcare 43.02%
2 Technology 23.53%
3 Industrials 12.87%
4 Consumer Discretionary 5.44%
5 Utilities 4.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EHC icon
101
Encompass Health
EHC
$11B
$11.6M 0.23%
194,495
– –
NTLA icon
102
Intellia Therapeutics
NTLA
$1.55B
$11.1M 0.22%
319,000
– –
BEAM icon
103
Beam Therapeutics
BEAM
$2.73B
$10.4M 0.21%
267,025
– –
TRGP icon
104
Targa Resources
TRGP
$57.6B
$10.3M 0.2%
139,561
+103,361
+286% +$7.21M
ALXO icon
105
ALX Oncology
ALXO
$262M
$10.2M 0.2%
902,000
– –
BAX icon
106
Baxter International
BAX
$13.8B
$10.1M 0.2%
198,600
– –
ICPT
107
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$9.9M 0.2%
800,000
– –
KDNY
108
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$9.66M 0.19%
+368,811
New +$8.17M
GXO icon
109
GXO Logistics
GXO
$5.8B
$9.39M 0.19%
220,000
– –
AMLX icon
110
Amylyx Pharmaceuticals
AMLX
$2.31B
$9.24M 0.18%
+250,000
New +$8.87M
MRTX
111
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.23M 0.18%
203,600
– –
RCKT icon
112
Rocket Pharmaceuticals
RCKT
$351M
$9.21M 0.18%
+470,654
New +$8.67M
APTV.PRA
113
DELISTED
Aptiv PLC 5.50% Series A Mandatory Convertible Preferred Shares
APTV.PRA
– –
-78,500
Closed -$8.64M
PRAX icon
114
Praxis Precision Medicines
PRAX
$8.58B
$8.37M 0.17%
234,537
– –
SWAV
115
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$8.16M 0.16%
39,700
– –
ELS icon
116
Equity Lifestyle Properties
ELS
$12.7B
$7.97M 0.16%
123,385
– –
EGP icon
117
EastGroup Properties
EGP
$11.3B
$7.52M 0.15%
50,808
+8
+0% +$1.21K
WD icon
118
Walker & Dunlop
WD
$1.68B
$7.42M 0.15%
94,535
– –
ADCT icon
119
ADC Therapeutics
ADCT
$141M
$7.22M 0.14%
1,879,959
– –
EQT icon
120
EQT Corp
EQT
$33B
$6.98M 0.14%
206,291
+124,357
+152% +$4.99M
SNV
121
DELISTED
Synovus
SNV
$6.91M 0.14%
184,028
+44,541
+32% +$1.77M
PLD icon
122
Prologis
PLD
$136B
$6.82M 0.13%
60,466
+50,066
+481% +$5.55M
DVN icon
123
Devon Energy
DVN
$50.9B
$6.62M 0.13%
+107,657
New +$7.34M
RCUS icon
124
Arcus Biosciences
RCUS
$3.55B
$4.96M 0.1%
+240,000
New +$6.6M
ARE icon
125
Alexandria Real Estate Equities
ARE
$9.15B
$4.71M 0.09%
32,335
– –
3 4
5
6 7

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2022 Portfolio in Review

As of Q4 2022, Eventide Asset Management held 159 positions worth $5.07B, down 0.23% from $5.08B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management's Q4 2022 filing shows 22 new, 53 increased, 27 reduced and 17 closed positions. Its largest new stake was Seagen Inc. Common Stock: 242,545 shares worth $31.2M. The largest sale was Cintas, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 39% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q4 2022 buy was Seagen Inc. Common Stock: 242,545 shares worth $31.2M.
  • Eventide Asset Management added most to Evolent Health in Q4 2022, an estimated $48.3M increase.
  • Eventide Asset Management's biggest Q4 2022 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $106M.
  • Eventide Asset Management fully exited Cintas in Q4 2022, selling an estimated $108M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $5.07B portfolio in Q4 2022.
  • Eventide Asset Management opened 22 new positions and closed 17 in Q4 2022.
  • Eventide Asset Management's portfolio value fell 0.23% quarter-over-quarter to $5.07B.

Based on Eventide Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.